SEC Form 4 · accession 0001144204-15-033347
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Brendan A Ford
Director
Period of report
May 21, 2015
Accepted (ET)
May 26, 2015 · 10:16 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 21, 2015 | A | 20,000 | $1.3113 | A | 230,633 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Weighted average of purchase prices ranging from $1.31 to $1.32 per share. Mr. Ford undertakes to provide upon request by the Staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price.